Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DXC014 in Advanced Solid Tumors
NCT07177937Phase 1Recruiting
- Sponsor
- Hangzhou DAC Biotech
- Start
- Mar 2026
- Primary completion
- Oct 2030
- Modality
- Bispecific Antibodies, Cytotoxic ADCs, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of dxc014 in small cell lung cancer (SCLC), melanoma, prostate cancer (PCa) and 1 more, sponsored by Hangzhou DAC Biotech. Primary endpoints: Dose Limiting Toxicities at 28 days and Adverse Events at 1 year. Started Mar 2026; status: recruiting.
02
Drugs
dxc014
03
Conditions
small cell lung cancer (SCLC)melanomaprostate cancer (PCa)solid tumor
Beyond the preview
Go deeper on NCT07177937.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07177937.